
Oncology medicines often reach the market on early data, but payers value overall survival and quality of life. The gap between regulatory and reimbursement evidence[…]

The Greek HTA Committee does not simply ask whether a medicine works. It weighs five distinct questions, and a dossier built around those questions is[…]

Speed to patients in Greece is shaped by a sequence of steps, not one decision. Published analysis of the national process shows where time is[…]

When no head-to-head trial exists, joint clinical assessment will still ask how your product compares. The methodological guidance adopted by the HTA Coordination Group sets[…]

A price can be justified on value and still fail on affordability. Budget impact analysis answers a different question from cost-effectiveness: what will this medicine[…]

The inverted black triangle in a package leaflet tells patients and healthcare professionals that a medicine is under additional monitoring. For the marketing authorisation holder[…]

For more than two decades, stability programmes have been designed around a patchwork of ICH guidelines: Q1A(R2) to Q1E and, for biologicals, Q5C. The draft[…]

ICH E6(R3) replaces the 2016 R2 text with a principles-based, risk-proportionate framework, and the EU has already put the first part into effect, with the[…]

A change that is well controlled on site can still create a compliance problem if nobody asked whether the marketing authorisation needs to be updated[…]

Management review is where a quality system proves it is more than a set of procedures: senior leadership examines performance data and decides what to[…]